Knight Therapeutics
Specialty pharmaceutical company focused on acquiring or in-licensing.
Launch date
Employees
Market cap
$445m
Enterprise valuation
$372m (Public information from Sep 2024)
Share price
CAD6.13 GUD.TO
Westmount Quebec (HQ)
Financials
Estimates*
| CAD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 200m | 243m | 294m | 328m | 360m | 372m | 392m |
| % growth | 320 % | 22 % | 21 % | 12 % | 10 % | 3 % | 5 % |
| EBITDA | 28.6m | 42.6m | 60.2m | 72.2m | 58.5m | 61.9m | 72.7m |
| % EBITDA margin | 14 % | 17 % | 21 % | 22 % | 16 % | 17 % | 19 % |
| Profit | 42.1m | 15.7m | (29.9m) | (16.8m) | (3.9m) | 13.4m | 13.2m |
| % profit margin | 21 % | 6 % | (10 %) | (5 %) | (1 %) | 4 % | 3 % |
| EV / revenue | 3.5x | 2.6x | 2.0x | 1.6x | 1.5x | 1.5x | 1.4x |
| EV / EBITDA | 24.3x | 14.8x | 9.7x | 7.5x | 9.5x | 9.0x | 7.6x |
| R&D budget | 11.7m | 12.7m | 14.8m | 17.5m | - | - | - |
| R&D % of revenue | 6 % | 5 % | 5 % | 5 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | $87.0m | Growth Equity VC | |
* | N/A | CAD230m | Post IPO Equity |
| N/A | CAD100m | Post IPO Equity | |
| N/A | N/A | Secondary | |
* | $38.5m | Post IPO Debt | |
| Total Funding | $87.0m | ||
Related Content
Recent News about Knight Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
